Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist
# Amycretin Dosing Guide: Oral Daily and Weekly Subcutaneous Protocols
> Note: PeptIQ is not a medical provider. Amycretin is investigational. Early-phase doses are not a consumer titration chart. Educational content only.
Amycretin is Novo Nordisk's unimolecular long-acting GLP-1 and amylin receptor agonist — one molecule hitting both pathways CagriSema attacks with two drugs. That dual biology is why "amycretin dosage" is becoming a high-intent query beside orforglipron and eloralintide.
Novo has advanced both oral (once daily) and subcutaneous (once weekly) formulations toward Phase 3 obesity development based on early clinical data published in The Lancet.
Quick Answer: Amycretin Dosing Formats
Format
Cadence
Early-phase dose anchors (public)
Subcutaneous amycretin
Once weekly
Dose-response exploration including 1.25 mg, 5 mg, and 20 mg maintenance-style exposures in Phase 1b/2a parts
Oral amycretin
Once daily
Early human study doses including 50 mg daily and higher (2×50 mg) over short windows
Exact Phase 3 maintenance ladders will supersede these early maps when protocols publish.
Subcutaneous Results People Cite
In a Phase 1b/2a randomized study of adults with overweight or obesity (n=125 in public summaries):
Exposure described
Approx. mean weight change
Approx. duration context
1.25 mg
~−9.7%
~20-week style public summary
5 mg
~−16%
~28-week style public summary
20 mg
~−22%
~36-week style public summary
Matching placebo arms
slight gain (~+2%)
same windows
Adverse events were predominantly gastrointestinal and mostly mild to moderate — class-consistent with incretin/amylin therapy when titrated.
Different press summaries sometimes quote alternate top-end figures depending on which analysis part they emphasize. Prefer the Lancet tables for citations.
Weight loss had not clearly plateaued by week 12 in early commentary — a classic "this will get more interesting with longer Phase 3" signal.
Compared with oral semaglutide, amycretin's dual agonist story + Novo's Phase 3 push makes it a direct competitor narrative to orforglipron (Lilly oral GLP-1) in search.
Amycretin vs CagriSema vs Eloralintide
Amycretin
CagriSema
Eloralintide
Design
One molecule: GLP-1 + amylin
Two molecules: sema + cagrilintide
Selective amylin agonist
Formats
Oral daily + SC weekly in development
Weekly combo injection story
Weekly SC
Early standout
Large % loss in small early SC cohorts
Large Phase 3 combo dataset
Phase 2 monotherapy ~9–20%
Amycretin is not "better CagriSema" by default — it is a different product architecture that may simplify administration if Phase 3 confirms efficacy and tolerability.
Titration Philosophy (Educational)
Early programs used careful escalation because dual pathway agonism can stack GI effects. Until Phase 3 labels exist:
Assume slow step-ups beat hero dosing
Log nausea for 48–72 hours after each increase
Protect protein (≥1.6 g/kg targets when appetite collapses)
Keep resistance training non-negotiable
What Phase 3 Should Clarify
Novo communicated plans to start Phase 3 in adults with overweight/obesity after end-of-phase-2 regulatory discussions, with program initiation targeted around early 2026 in company timelines. Watch for:
Final oral vs SC dose ladders
68–72+ week weight curves
Discontinuation rates vs semaglutide / CagriSema benchmarks
Whether oral amycretin needs food/water rules (orforglipron-style convenience is a competitive flashpoint)
FAQ
Q: What is the amycretin dose for weight loss?
A: There is no approved dose. Early SC exploration publicly highlighted 1.25 / 5 / 20 mg weekly-style exposures; oral work explored ~50 mg daily and higher short-term. Phase 3 will define labeled titration.
Q: Is amycretin a peptide injection or a pill?
A: Both formats are in development — once-weekly subcutaneous and once-daily oral.
Q: Is amycretin the same as CagriSema?
A: No. CagriSema combines two drugs. Amycretin is a single dual agonist molecule.
Q: How does amycretin compare to retatrutide?
A: Different receptor map. Retatrutide is GLP-1/GIP/glucagon. Amycretin is GLP-1/amylin. Compare trials, not vibes.
Bottom Line
Amycretin dosing is a two-track story: early SC weekly exposures up through ~20 mg with very large mean losses in small cohorts, plus oral daily doses in the ~50 mg range over short windows — now heading into Phase 3. Track pathway literacy (GLP-1 + amylin in one molecule) and wait for the formal ladders.
Download PeptIQ to log oral daily or weekly injectable metabolic protocols in one place.
